The NOAC and warfarin groups both showed a lower cumulative risk of efficacy outcomes compared with the no-treatment group (A). Warfarin group has the highest cumulative risk of safety outcome, while the no-treatment had the lowest cumulative risk of safety event (B). The weighted cumulative risk of composite outcome showed a clear separation of event curves within the three groups, in which the NOAC group had the lowest risk of composite outcome, while the no-treatment group had the highest risk of composite outcome (C).</p
<p>Cumulative proportions of patients reporting one or several risk factors and resulting number-to-...
Hazard ratio adjusted with age, sex, previous history of hypertension, diabetes mellitus, congestive...
<p>Cumulative HIV-1 incidence curves for vaccine and placebo groups for Phambili and Phambili + HVTN...
Cumulative incidence curves showing the probability of initiating treatment for low-risk patients (g...
Cumulative incidence rates for all-cause death/myocardial infarction in overall (A) and matched (B) ...
The NOAC group showed lower risks of safety and composite outcome to the warfarin group with TTR of ...
The adjusted risk of outcomes for those patients taking oral anticoagulants in relative to no-treatm...
In general, the warfarin group with aTTR in the range from 70% showed a decremental risk of efficac...
<p>The number at risk in each group is shown in the footnote lines. Patients in the sub-cohort who d...
<p>Cumulative incidence curves applied in the testing set to assess the competing mortality risks in...
<p>Left: Composite endpoint of stroke, bleeding and death. Right: Readmission with atrial fibrillati...
<p>The estimated cumulative incidences of all-cause death (A), MI (B), ST (C), TVR (D) and MACE (E) ...
Hazard ratio adjusted with age, sex, previous history of hypertension, diabetes mellitus, congestive...
A) Cumulative incidence of the primary outcome measure (all cause death); normal versus high RWT gro...
HF, heart failure; No, number; Non-HT, without hypertension; HT, hypertension; RAS-i, renin-angioten...
<p>Cumulative proportions of patients reporting one or several risk factors and resulting number-to-...
Hazard ratio adjusted with age, sex, previous history of hypertension, diabetes mellitus, congestive...
<p>Cumulative HIV-1 incidence curves for vaccine and placebo groups for Phambili and Phambili + HVTN...
Cumulative incidence curves showing the probability of initiating treatment for low-risk patients (g...
Cumulative incidence rates for all-cause death/myocardial infarction in overall (A) and matched (B) ...
The NOAC group showed lower risks of safety and composite outcome to the warfarin group with TTR of ...
The adjusted risk of outcomes for those patients taking oral anticoagulants in relative to no-treatm...
In general, the warfarin group with aTTR in the range from 70% showed a decremental risk of efficac...
<p>The number at risk in each group is shown in the footnote lines. Patients in the sub-cohort who d...
<p>Cumulative incidence curves applied in the testing set to assess the competing mortality risks in...
<p>Left: Composite endpoint of stroke, bleeding and death. Right: Readmission with atrial fibrillati...
<p>The estimated cumulative incidences of all-cause death (A), MI (B), ST (C), TVR (D) and MACE (E) ...
Hazard ratio adjusted with age, sex, previous history of hypertension, diabetes mellitus, congestive...
A) Cumulative incidence of the primary outcome measure (all cause death); normal versus high RWT gro...
HF, heart failure; No, number; Non-HT, without hypertension; HT, hypertension; RAS-i, renin-angioten...
<p>Cumulative proportions of patients reporting one or several risk factors and resulting number-to-...
Hazard ratio adjusted with age, sex, previous history of hypertension, diabetes mellitus, congestive...
<p>Cumulative HIV-1 incidence curves for vaccine and placebo groups for Phambili and Phambili + HVTN...